Skip to search formSkip to main contentSkip to account menu

ALK/TRK Inhibitor TSR-011

Known as: TSR-011 
An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Belizatinib: Novel reactive intermediates and bioactivation pathways characterized by LC-MS/MS.
Review
2016
Review
2016
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK… 
2015
2015
Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.
8063 Background: Both intrinsic and acquired resistance mechanisms to ALK inhibitors have been observed in ALK rearranged (ALK… 
Review
2015
Review
2015
The next-generation ALK inhibitors
Purpose of review Crizotinib now is accepted as the standard first-line treatment of ALK-rearranged lung adenocarcinomas. To… 
Review
2015
Review
2015
Anaplastic Lymphoma Kinase as a Therapeutic Target in Non–Small Cell Lung Cancer
AbstractThe therapeutic targeting of anaplastic lymphoma kinase (ALK) has been a burgeoning area of research since 2007 when ALK… 
2014
2014
Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.
e19005 Background: Ultimately, the majority of anaplastic lymphoma kinase (ALK) rearranged (+) non-small cell lung cancers (NSCLC… 
2014
2014
506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)